Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Intra-Cellular Therapies, Inc.

A Decade of SG&A: AstraZeneca vs. Intra-Cellular Therapies

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, AstraZeneca PLC and Intra-Cellular Therapies, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global giant, has seen its SG&A costs rise by approximately 35% from 2014 to 2023, peaking in 2022. This reflects its expansive global operations and strategic investments. In contrast, Intra-Cellular Therapies, a burgeoning biotech firm, has experienced a staggering 3,860% increase in SG&A expenses, indicative of its rapid growth and market penetration efforts. While AstraZeneca's expenses dwarf those of Intra-Cellular Therapies, the latter's growth rate underscores its aggressive expansion strategy. This analysis offers a window into the operational strategies of two distinct players in the pharmaceutical sector, highlighting the balance between growth and cost management.